Los Angeles, California — Plexus Ventures is pleased to announce the successful completion of its most recent divestment project. Plexus provided professional services to Novartis Consumer Health in the divestiture of an OTC product having European sales to a regionally strong European company.
- Plexus Ventures Assists Elthera AG in the Licensing of its First-in-Class Antibody
- Celon Pharma enters agreement with Zydus Lifesciences Ltd.
- Mindpax engages Plexus Ventures as Exclusive Advisor to Partner its Digital Platform for Severe Mental Illnesses
- Plexus Ventures’ Important Company Announcement
- Plexus Ventures Assists Valeas S.p.A. to acquire from Pharmactive Biotech Products, SL, Spain licensing and distribution rights for its premium Affron®-based product for commercialization in Italy